RNAi has great promise as a therapeutic but biological hurdles must be overcome before the dream is realized.
FDA and drug companies alike want ADME-tox testing performed earlier and earlier in a drug’s life cycle.
Neuroimaging has become a powerful biomarker and helps researchers study mental illness. What impact will real-time imaging have in unraveling the mysteries of neurological diseases?
The search for the perfect blockbuster biomarker for Alzheimer’s Disease is on. Pharmaceutical companies need better tools to develop novel therapeutics. Patients and physicians need better tools for early and accurate diagnosis.
In many areas of life science, researchers want to work on living cells and track interactions such as how proteins interact and where. That often requires fluorescent markers, and scientists keep making new ones.
The US Food and Drug Administration (FDA) appears to be taking a cautious, deliberative approach as it approaches the myriad of scientific and regulatory issues involving nanobiotechnology and nanomedicine.
If, like other readers, your top priority is to accelerate the drug discovery and development process, we have some new features in this issue to help you find information faster.
As more drug discovery and development processes cross borders, drug researchers must make sure that drug safety does not get lost in translation.
When researchers discovered that some genes could produce multiple forms of mRNA, they thought the phenomenon was rare. Now, alternative splicing of gene transcripts may be the rule, not the exception, and genomics researchers need to adapt their experimental strategies.
As they learn more about the genetic reasons for aging and cell death, researchers have already made aging a "curable disease" in model organisms. If similar successes can be achieved in humans, science will once again confront an ethical barrier.
PK/PD scientists are using computer-assisted modeling more than ever.
With the discovery of RNAi in the late 1990s, researchers had a whole new collection of experimental and therapeutic tools. Recent work on microRNA is now uncovering a surprising new level of natural gene regulation.
G&P June, 2005 Editorial
Despite constraints, the solid commitment of federal funding, along with a willing army of code contributors, bode well for the future of open-source bioinformatics. However, standardization and quality control remain concerns for this decentralized phenomenon.
Computational methods that can predict the structure of a protein from its amino acid sequence are improving. Developers of such programs say that the technology may one day completely supplant experimental structure determination.